Your browser is no longer supported. Please, upgrade your browser.
Settings
STML Stemline Therapeutics, Inc. daily Stock Chart
STML [NASD]
Stemline Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.00 Insider Own8.40% Shs Outstand46.70M Perf Week-9.18%
Market Cap577.68M Forward P/E- EPS next Y-0.49 Insider Trans-5.74% Shs Float39.08M Perf Month7.10%
Income-85.00M PEG- EPS next Q-0.63 Inst Own47.70% Short Float8.94% Perf Quarter26.10%
Sales0.50M P/S1155.36 EPS this Y-1.80% Inst Trans1.29% Short Ratio4.70 Perf Half Y-29.11%
Book/sh1.47 P/B8.41 EPS next Y76.60% ROA-96.70% Target Price30.38 Perf Year-10.69%
Cash/sh1.29 P/C9.58 EPS next 5Y- ROE-123.60% 52W Range7.82 - 20.55 Perf YTD30.21%
Dividend- P/FCF- EPS past 5Y-5.00% ROI-204.50% 52W High-39.81% Beta1.18
Dividend %- Quick Ratio3.00 Sales past 5Y47.80% Gross Margin- 52W Low58.18% ATR0.73
Employees92 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)52.43 Volatility6.56% 6.20%
OptionableYes Debt/Eq0.00 EPS Q/Q0.00% Profit Margin- Rel Volume0.80 Prev Close13.26
ShortableYes LT Debt/Eq0.00 EarningsMar 29 BMO Payout- Avg Volume743.94K Price12.37
Recom1.80 SMA201.69% SMA509.41% SMA200-10.92% Volume594,660 Change-6.71%
Dec-11-18Initiated JP Morgan Overweight $17
Nov-26-18Initiated Piper Jaffray Overweight $20
Jun-12-18Initiated ROTH Capital Buy $30
Nov-01-17Reiterated H.C. Wainwright Buy $34 → $38
Feb-06-17Reiterated Wedbush Outperform $19 → $11
Mar-15-16Reiterated Wedbush Outperform $19 → $15
Apr-27-15Initiated H.C. Wainwright Buy $38
Apr-22-15Resumed Jefferies Buy
Jan-26-15Reiterated ROTH Capital Buy $62 → $50
Oct-30-13Reiterated Aegis Capital Buy $40 → $70
Mar-18-19 07:00AM  Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference GlobeNewswire -5.29%
Mar-15-19 04:18PM  Stemline Therapeutics: 4Q Earnings Snapshot Associated Press
04:01PM  Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results GlobeNewswire
Mar-11-19 07:00AM  Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline GlobeNewswire
Mar-06-19 07:30AM  Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-19-19 11:30AM  Is Stemline Therapeutics, Inc. (NASDAQ:STML) Excessively Paying Its CEO? Simply Wall St.
Jan-30-19 07:30AM  Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) GlobeNewswire
Jan-24-19 07:55AM  Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-21-19 10:20AM  Read This Before Buying Stemline Therapeutics, Inc. (NASDAQ:STML) Shares Simply Wall St.
Jan-18-19 11:21AM  Stemline Therapeutics Closes $92 Million Public Offering of Common Stock GlobeNewswire
Jan-16-19 09:01AM  Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher Zacks
Jan-15-19 10:04PM  Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock GlobeNewswire +9.47%
Jan-14-19 04:35PM  Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -8.19%
Jan-07-19 09:50AM  Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS GlobeNewswire
Jan-02-19 07:30AM  Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-26-18 12:31PM  Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation Benzinga +12.55%
09:34AM  Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal Zacks
Dec-22-18 08:25AM  Why We Think Stemline Therapeutics, Inc. (NASDAQ:STML) Could Be Worth Looking At Simply Wall St.
Dec-21-18 02:55PM  FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy PR Newswire -5.18%
01:49PM  U.S. FDA approves Stemline Therapeutics' rare blood disease treatment Reuters
12:25PM  These 4 Biotech Stocks Are Raising Eyebrows ACCESSWIRE
Dec-07-18 01:29PM  Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst SmarterAnalyst
07:00AM  3 Biotech Stocks That Could Explode Higher in 2019 SmarterAnalyst
Dec-06-18 07:00AM  Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-30-18 07:00AM  Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting GlobeNewswire +8.60%
Nov-27-18 08:30AM  Report: Developing Opportunities within Koppers, Flowers Foods, Stemline Therapeutics, Aqua Metals, athenahealth, and Bojangles' Future Expectations, Projections Moving into 2018 GlobeNewswire -11.98%
Nov-21-18 02:59PM  What Kind Of Investor Owns Most Of Stemline Therapeutics Inc (NASDAQ:STML)? Simply Wall St. +11.40%
Nov-20-18 07:00AM  Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA) GlobeNewswire
Nov-16-18 07:30AM  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO) GlobeNewswire
Nov-08-18 05:17PM  Stemline Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Stemline Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-02-18 07:30AM  Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting GlobeNewswire
Oct-16-18 07:30AM  Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming ESMO 2018 Congress GlobeNewswire +6.21%
Oct-11-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Casella Waste, ServiceNow, MKS Instruments, FirstEnergy, Stemline Therapeutics, and CMS Energy Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-09-18 05:50PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML Business Wire
Sep-28-18 07:00AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-18-18 02:37PM  When Will Stemline Therapeutics Inc (NASDAQ:STML) Turn A Profit? Simply Wall St.
Sep-05-18 07:00AM  Stemline Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-14-18 07:30AM  Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-13-18 09:25AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  Stemline Therapeutics Announces that FDA Accepts ELZONRIS Biologics License Application (BLA) and Grants Priority Review GlobeNewswire
Aug-09-18 08:18AM  Stemline Therapeutics: 2Q Earnings Snapshot Associated Press +5.63%
08:00AM  Stemline Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-06-18 07:55AM  Report: Developing Opportunities within Stemline Therapeutics, Silgan, CVR Energy, MINDBODY, FireEye, and Quality Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-25-18 07:00AM  Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN GlobeNewswire
Jun-19-18 10:00AM  Biotechnology Firm PPCB, Shows Great Potential ACCESSWIRE
Jun-18-18 07:00AM  Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress GlobeNewswire
Jun-15-18 08:15AM  Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress GlobeNewswire
Jun-14-18 07:00AM  Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress GlobeNewswire
Jun-05-18 07:00AM  Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO GlobeNewswire
May-22-18 07:20AM  Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress ACCESSWIRE
May-18-18 07:00AM  Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress GlobeNewswire
May-17-18 07:00AM  Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting GlobeNewswire
May-09-18 04:26PM  Stemline Therapeutics: 1Q Earnings Snapshot Associated Press
04:00PM  Stemline Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 06:04PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Stemline Therapeutics, Inc. Business Wire
May-01-18 01:43PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-30-18 08:25AM  Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-26-18 07:00AM  Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire
Apr-09-18 07:10AM  Wired News Stemline Therapeutics Initiates Rolling BLA Submission for SL-401 ACCESSWIRE +7.28%
Apr-05-18 07:00AM  Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401 GlobeNewswire
Mar-19-18 07:50AM  Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:30AM  Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-16-18 08:05AM  Stemline Therapeutics reports 4Q loss Associated Press -6.33%
07:30AM  Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results GlobeNewswire
Mar-14-18 07:34AM  Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML) Simply Wall St.
Mar-08-18 07:30AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-30-18 11:02AM  Top 3 Growth Stocks For The Month Simply Wall St.
Jan-26-18 10:21AM  Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock GlobeNewswire +6.41%
Jan-24-18 07:00AM  Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock GlobeNewswire +7.77%
Jan-22-18 04:01PM  Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +5.17%
Jan-09-18 07:30AM  Detailed Research: Economic Perspectives on Fluidigm, Stemline Therapeutics, NeoGenomics, CVR Energy, W.R. Berkley, and Mack-Cali Realty What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-08-18 02:24PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML Business Wire -5.12%
Jan-04-18 08:00AM  Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.00%
Dec-26-17 12:11PM  ETFs with exposure to Stemline Therapeutics, Inc. : December 26, 2017 Capital Cube
Dec-25-17 11:02AM  Best-In-Class Growth Stocks Simply Wall St.
09:26AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-13-17 08:47AM  Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment MarketWatch
08:36AM  Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented GlobeNewswire
Dec-08-17 07:00AM  Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting GlobeNewswire
Nov-16-17 07:00AM  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO) GlobeNewswire
Nov-09-17 05:14PM  Stemline Therapeutics reports 3Q loss Associated Press
04:01PM  Stemline Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 12:29PM  Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in October Motley Fool -6.01%
Nov-04-17 03:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Nov-02-17 12:35PM  ETFs with exposure to Stemline Therapeutics, Inc. : November 2, 2017 Capital Cube
Nov-01-17 09:02AM  Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting GlobeNewswire
Oct-31-17 04:21PM  The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% Motley Fool +29.38%
12:02PM  Growth Stocks Investors Love Simply Wall St.
07:00AM  Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint GlobeNewswire
Sep-20-17 07:00AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-11-17 07:00AM  Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 GlobeNewswire
Sep-08-17 07:30AM  Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-31-17 09:14PM  ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-30-17 06:10PM  Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress GlobeNewswire
Aug-24-17 10:51AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-14-17 07:30AM  Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-08-17 05:48PM  Stemline Therapeutics reports 2Q loss Associated Press
07:00AM  Stemline Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoberman KennethChief Operating OfficerMar 12Sale11.0498110,830755,696Mar 15 09:00 PM
Gionco DavidChief Accounting OfficerMar 12Sale11.055305,857224,938Mar 15 09:00 PM
Bergstein IvanChief Executive OfficerMar 12Sale11.052,15123,7692,662,127Mar 15 09:01 PM
Bergstein IvanChief Executive OfficerMar 11Sale11.1155,073611,8612,664,278Mar 15 09:01 PM
Gionco DavidChief Accounting OfficerMar 11Sale11.1113,492149,896225,468Mar 15 09:00 PM
Hoberman KennethChief Operating OfficerMar 11Sale11.1125,101278,872756,677Mar 15 09:00 PM
Hoberman KennethChief Operating OfficerMar 07Sale11.362,99534,023781,778Mar 08 09:31 PM
Bergstein IvanChief Executive OfficerMar 07Sale11.416,80077,5882,719,351Mar 08 09:30 PM
Gionco DavidChief Accounting OfficerMar 07Sale11.321,38115,633238,960Mar 08 09:30 PM
Gionco DavidChief Accounting OfficerFeb 25Sale12.038,563103,013240,341Feb 27 09:10 PM
Bergstein IvanChief Executive OfficerFeb 25Sale12.0322,905275,5472,726,151Feb 27 09:09 PM
Hoberman KennethChief Operating OfficerFeb 25Sale12.0510,557127,212784,773Feb 27 09:10 PM
Bergstein IvanChief Executive OfficerFeb 14Sale10.9834,132374,7692,749,056Feb 15 09:31 PM
Hoberman KennethChief Operating OfficerJan 08Sale10.1513,547137,502646,652Jan 11 09:30 PM
Hoberman KennethChief Operating OfficerNov 26Sale11.8526,296311,608659,738Nov 30 08:59 PM